XIIth Eurasian Hematology-Oncology Congress (EHOC)

XIIth Eurasian Hematology-Oncology Congress (EHOC) is organized by Eurasian Hematology-Oncology Congress (EHOC) and will be held from Nov 10 - 13, 2021 at Hilton Istanbul Bomonti Hotel & Conference Center, Istanbul, Turkey. This conference is also held as Virtual.

Description:
The attendees will be able to enjoy scientific programs in both Adult Hematology & Pediatric Hematology / Oncology as well as Nursing.

 

Attendees will be able to access the virtual congress content with the account information that will be sent to the e-mail address they have registered, and only one user will be allowed to participate in the online sessions with one device at the same time.

 

Oral Presentation Sessions

Oral presentation sessions will be held in different halls based on the category that they were submitted to, the authors will present their works in the main hall live within the specified time.

 

Important Days:
Abstract Submission Deadline : August 23, 2021 / 23:59 (local time)
Early Registration Deadline: September 30, 2021 / 23:59 (local time)

.

Session Details:

TIME 10 NOVEMBER 2021   ADULT HEMATOLOGY PROGRAM - GUEST SOCIETY DAY NURSING PROGRAM 08.20 - 08.30 OPENING REMARKS OF EHOC 2021   SESSION 1 - SMOP SESSION Mind the Gap: Outcomes, Trends and Lessons Learned SESSION 1  08.30 - 08.45 Patterns of Treatments & Outcomes In Relapsed DLBCL in LMICs Acute Leukemias: Treatment Models, Tissue Typing and Treatment Pathways 08.45 - 09.00 Predictors of Outcomes and Survival Analysis in Prostate Cancer-Data From A  Tert?ary Care Urology Instiute 09.00 - 09.15 Colorectal Cancer: Local Perspective in the Era of Precision Medicine Thalassamia & Nursing Concern 09.15 - 09.30 GENERAL DISCUSSION     Iron Cehalation: Why Important?   SESSION 2 - ISRAEL SOCIETY OF HEMATOLOGY SYMPOSIUM  09.30 - 09.50 Digital Tools in Medicine in 2021 Data Managers: Collecting Data & Clinical Audits 09.50- 10.10 Treating AML in the Era of Targeted Therapy - Challenges and Opportunities  10.10 - 10.20 GENERAL DISCUSSION 10.20 - 10.40  COFFEE BREAK   SESSION 3 - ELN HIGHLIGHTS SESSION : ELN: Progress with Chronic Leukemias SESSION 2    10.40 - 10.55 ELN Recommendations for Treating CML  Heamatological Emergencies and Utilising EWS Scoring 10.55 - 11.10 ELN Recommendations for Treating MDS How Covid Pandemi Changed Our Clinical Practice 11.10 - 11.25 ELN Recommendations for Treating MPN End Of Line in Amidst of Pandemic 11.25 - 11.40 GENERAL DISCUSSION 11.40 - 12.20 SATELLITE SYMPOSIUM SATELLITE SYMPOSIUM   SESSION 4 - ROHS SESSION SESSION 3    12.20 - 12.40 Target and Immunotherapy in Patients with Agressive B Cell Lymphoma: Pavlov University Experience The Role of Practice Facilitator: How to Develop Nurses in Cancer Setting? 12.40 - 13.00 Allogeneic Hematopoetic Stem Cells Transplantation for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma in the Era of Immunotherapy Looking After Young Adults & Chalenges: Grey Zone 13.00 - 13.10 GENERAL DISCUSSION 13.10 - 14.10 LUNCH BREAK   SESSION 5 - ABHH SESSION                           SESSION 4    14.10 - 14.25 Generic Imatinib x Gleevec Therapeutic Use of Apheresis in Cancer sSetting 14.25 - 14.40 T-CELL Project 14.40 - 14.55 CAR-T Cell 14.55 - 15.10 GENERAL DISCUSSION 2nd TOPIC   SESSION 6:  ASFA SESSION Pscyhological Support for Cancer Patient 15.10 - 15.25 Preparation and Changes to Apheresis Facilities Practices During the COVID-19 Pandemic 15.25 - 15.40 The Use of Apheresis , E.G.  TPE in Patients with COVID-19 Mouthcare and Assessment Tool 15.40 - 15.55 The Use of TPE in Alzheimer's Disease -The AMBAR Study 15.55 - 16.10 Review of New Indication - Journal of Clinical Apheresis Preseptective Blood Transfusion: Why Irradiated? 16.10 - 16.30 GENERAL DISCUSSION 16.30 - 16.50  COFFEE BREAK   SESSION 7 - AABB SESSION                           SESSION 5    16.50 - 17.10 Biomanufacturing Challenges in Advanced Cell Therapies Heamophilia & Nursing  17.10 - 17.30 Hematopoietic Cell Transplantation: Lessons Learned and Future Direction 17.30 - 17.40 GENERAL DISCUSSION Sickle & Nursing Care   SESSION 8 - HIGHLIGHTS OF SOHO SESSION                           Inducing Early Menopause to Cancer Patients 17.40 - 17.55 SOHO State of the Art & Next Questions: AML 17.55 - 18.10 SOHO State of the Art & Next Questions: ALL Haplo Transplant and Nursing Concerns Care 18.10 - 18.25 SOHO State of the Art & Next Questions: MDS 18.25 - 18.40 SOHO State of the Art & Next Questions: CLL 18.40 - 19.00 GENERAL DISCUSSION CLOSING   TIME 11 NOVEMBER 2021   ADULT HEMATOLOGY PROGRAM - GUEST SOCIETY DAY PEDIATRIC HEMATOLOGY & ONCOLOGY PROGRAM 07.40 - 08.00 ORAL PRESENTATION SESSIONS 1         08.00 - 08.20 08.20 - 08:40   ADULT & PEDIATRIC ONCOLOGY JOINT SESSION JOINT SESSION IN BASIC ONCOLOGY  08.40 - 09.00 Genetic Predisposition to Pediatric Cancer 09.00 - 09.20 Precision Medicine in Cancer 09.20 - 09.40 Inflammation and Cancer 09.40 - 10.00 Cancer Stem Cells: Theories and Facts 10.00 - 10.20 GENERAL DISCUSSION  10.20 - 10.40 COFFEE BREAK   ADULT & PEDIATRIC HEMATOLOGY JOINT SESSION IN HAEMOGLOBINOPATHIES  10.40 - 11.00 Evaluation of Iron Load in Patients with Haemoglobinopathy  11.00 - 11.20 BMT in Children with Thalassemia in Turkey 11.20 - 11.40 Thalassemia Treatment 11.40 - 12.00 Treatment of Sickle Cell in 2021 12.00 - 12.20 GENERAL DISCUSSION  12.20 - 12.40 LUNCH BREAK 12.40 - 13.00 13.00 - 13.20 13.20 - 13.40 SATELLITE SYMPOSIUM SATELLITE SYMPOSIUM 13.40 - 14.00   SESSION 9 - CHRONIC MYELOID LEUKEMIA  SESSION 1 - COMPLICATIONS IN BMT 14.00 - 14.20 Second and Third-Line CML Therapy Late Effects of TBI and Busulfan 14.20 - 14.40 How Can We Implement TFR in Clinical Practice? TMA Diagnosis and Treatment  14.40 - 15:00 New TKIs and Their Role in CML Therapy VOD: Diagnosis and Treatment   15.00 - 15.20 Still a Role for IFN in CML?   15.20 - 15.40 GENERAL DISCUSSION  GENERAL DISCUSSION 15.40 - 16.00 COFFEE BREAK   SESSION 10 - MULTIPLE MYELOMA SESSION 2 - RECENT ADVANCES IN LEUKEMIA 16.00 - 16.20 MRD Detection in MM: Methods and Prognostic Significance New Advances in ALL Treatment 16.20 - 16.40 Treatment of Relapsed, Refractory Multiple Myeloma: Focus on New Drugs New Advances in AML Treatment 16.40 - 17.00 First Line Therapy for Multiple Myeloma: Open Issues Advances in the Diagnosis and Treatment of MDS  17.00 - 17.20 Management of Waldenstrom Macroglobulinemia in 2020     17.20 - 17.40 GENERAL DISCUSSION  GENERAL DISCUSSION 17.40 - 18.00 SATELLITE SYMPOSIUM SATELLITE SYMPOSIUM 18.00 - 18.20 18.20 - 18.40 E-POSTER PRESENTATIONS SESSION  18.40 - 19.00 19.00 - 19.20   TIME 12 NOVEMBER 2021   ADULT HEMATOLOGY PROGRAM  PEDIATRIC HEMATOLOGY & ONCOLOGY PROGRAM 07.40 - 08.00 ORAL PRESENTATION SESSIONS 2 08.00 - 08.20 08.20 - 08:40   SESSION 12 - PNH and COAGULATION PROBLEMS SESSION 3 - CONGENITAL BONE MARROW FAILURE SYNDROMES   08.40 - 09.00 Hemophilia Diamond Blackfan Anemia 09.00 - 09.20 ITP Dyskeratosis Congenita 09.20 - 09.40 PNH Congenital N Eutropenias: Turkish Registry 09.40 - 10.00 Coumadin and New Oral Anticoagulants: Which and When 10.00 - 10.20 GENERAL DISCUSSION  GENERAL DISCUSSION 10.20 - 10.40 COFFEE BREAK   SESSION 13 -  CHRONIC LYMPHOCYTIC LEUKEMIAS AND INDOLENT LYMPHOMAS SESSION 4 - PLATELET DISORDERS 10.40 - 11.00 Current Therapy of CLL New Treatments in ITP  11.00 - 11.20 Indolent Lymphomas Hereditary Macrothrombocyte Disorders 11.20 - 11.40 New Drugs for Low Grade lymphoproliferative Disease Thrombocytosis in Children 11.40 - 12.00 Can We Cure CLL? 12.00 - 12.20 GENERAL DISCUSSION  GENERAL DISCUSSION 12.20 - 12.40 LUNCH BREAK 12.40 - 13.00 13.00 - 13.20 13.20 - 13.40 SATELLITE SYMPOSIUM SATELLITE SYMPOSIUM 13.40 - 14.00   SESSION 14 - SPECIAL TOPICS FOR LYMPHOMAS   SESSION 5 - THROMBOSIS IN CHILDREN 14.00 - 14.20 Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma Thrombosis in the Newborn 14.20 - 14.40 Treatment of R/R Hodgkin Lymphoma New Anticoagulant Treatments in Children 14.40 - 15:00 Response Adapted Maintenance Therapy in FL:Lessons from the FOLL12 Trial CNS Thrombosis  15.00 - 15.20 Treatment of R/R Follicular Lymphoma 15.20 - 15.40 GENERAL DISCUSSION  GENERAL DISCUSSION 15.40 - 16.00  COFFEE BREAK   SESSION 15 - TRANSPLANTATION  SESSION 6 - HOGKIN LYMPHOMA IN CHILDHOOD AND ADOLESCENT 16.00 - 16.20 Haplo vs MUD Transpplant Medical Treatment in Hodgkin Lymphomas 16.20 - 16.40 GVHD Treatment Radiotherapy in Hodgkin Lymphoma 16.40 - 17.00 Car-T Cell Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma 17.00 - 17.20 Reduced Intensity Conditioning Treatment: Current View  17.20 - 17.40 GENERAL DISCUSSION  GENERAL DISCUSSION 17.40 - 18.00 SATELLITE SYMPOSIUM SATELLITE SYMPOSIUM 18.00 - 18.20   SESSION 16 -   ACUTE LYMPHOBLASTIC LEUKEMIA SESSION 7 - LATE SIDE EFFECTS IN PEDIATRIC CANCER 18.20 - 18.40 European Vision of ALL Treatment Late Effects of Childhood Cancer: The Foundation for Risk-Stratified Pediatric Cancer Care 18.40 - 19.00 American Vision of ALL Treatment Rehabilitation for Children Adolescents and Young Adults with Sarcoma 19.00 - 19.20 Acute T-ALL Update on Fertility Preservation 19.20 - 19.40 Ph-positive ALL 19.40 - 20.00 GENERAL DISCUSSION  GENERAL DISCUSSION   TIME 13 NOVEMBER 2021   ADULT HEMATOLOGY PROGRAM  PEDIATRIC HEMATOLOGY & ONCOLOGY PROGRAM 07.40 - 08.00 ORAL PRESENTATION SESSIONS 3 08.00 - 08.20 08.20 - 08:40   SESSION 11- ACUTE MYELOID LEUKEMIA SESSION 8 - SUPPORTIVE CARE IN CHILDHOOD CANCER 08.40 - 09.00 Essential Molecular Characterisation of AML Patients Nutritional Support in Children with Cancer 09.00 - 09.20 How I Treat AML Principle of Tranfusion in Children with Cancer 09.20 - 09.40 Targeted Therapy in AML Treatment Pain Management in Children with Cancer 09.40 - 10.00 Importance of M?n?mal Residual Diesease Detection in AML Treatment 10.00 - 10.20 GENERAL DISCUSSION  GENERAL DISCUSSION 10.20 - 10.40 COFFEE BREAK   Session 12 : Ph-negative MPNs  SESSION 9 - BONE SARCOMA IN CHILDHOOD AND ADOLESCENT 10.40 - 11.00 How I Treat Policytemia Vera Medical Treatment in Osteosarcoma 11.00 - 11.20 How I Treat Myelofibrosis Medical Treatment in Ewing Sarcoma 11.20 - 11.40 Predictors of Response to Ruxolitinib in Myelofibrosis Surgical Treatment in Bone Sarcomas 11.40 - 12.00 How I treat Essential Thrombocythemia 12.00 - 12.20 GENERAL DISCUSSION  GENERAL DISCUSSION 12.20 - 12.40 LUNCH BREAK 12.40 - 13.00 13.00 - 13.20 13.20 - 13.40 SATELLITE SYMPOSIUM SATELLITE SYMPOSIUM 13.40 - 14.00   Session 13: MDS SESSION 10 - SOFT TISSUE SARCOMA IN CHILDHOOD AND ADOLESCENT 14.00 - 14.20 Novel Dynamic Outcome Indicators in MDS Medical Treatment in Rhabdomyosarcomas 14.20 - 14.40 How I Treat MDS Medical Treatment in Non-Rhabdomyosarcoma Soft Tissue Sarcomas 14.40 - 15:00 New Drugs for MDS Radiotherapy in Bone and Soft Tissue Sarcoma 15.00 - 15.20 Luspatercept in MDS 15.20 - 15.40 GENERAL DISCUSSION  GENERAL DISCUSSION  15.40 - 16.00  COFFEE BREAK   Session 14:  NEW BIOLOGICAL INSIGHTS INTO THE HEMATOLOGICAL DISEASES      16.00 - 16.15 Evolution of the Pleural Secretome Associated with Pleural Metastasis.     16.15 - 16.30 Intrapleural Therapy to Drive Systemic Anti-Tumor Immunity     16.30 - 16.45 The Promising Role of the hDHODH Inhibitors in the Therapy of Acute and Chronic Myeloid Leukemias     16.45 - 17.00 Evolution of Malignant Cells and Darwin     17.00 - 17.15 Congenital Erythrocyte Defects of the Paediatric Age     17.15 - 17.40 GENERAL DISCUSSION      17.40 CLOSING